Introduction
The normal premenopausal ovary is an important source of androgen as well as estrogen production. In premenopausal women, the daily testosterone production is approximately 300 mcg (1), of which approximately half is derived from the ovaries and half from the adrenal glands (1, 2) . Young women with spontaneous premature ovarian failure (sPOF) may have lower androgen levels compared with normal ovulatory women (3) (4) (5) .
In this pilot study, we investigate the steady-state pharmacokinetics, safety and tolerability of an investigational testosterone transdermal patch designed to deliver 150 mcg/day (TTP; Watson Laboratories, Inc. and Procter & Gamble Pharmaceuticals) in young women with sPOF receiving standard sequential estrogen/ progestogen therapy.
The primary objective was to assess the serum concentration profiles of free and total testosterone before and during application of the TTP. Secondary objectives were to evaluate serum estradiol and SHBG levels, local tolerability and the effects of the TTP on vaginal bleeding patterns and clinical safety parameters.
Experimental Subjects
This pilot study was approved by the Institutional Review Board of the National Institute of Child Health and Human Development, National Institutes of Health (Bethesda, MD).
All women provided informed written consent. Nine women with sPOF were recruited for this study from those that had participated in a screening protocol (6) . To be eligible for the study, women had to fulfill the following inclusion criteria: 1) diagnosis of sPOF before the age of 40 yr; 2) age between 18 and 42 years; 3) no hysterectomy; 4) no contraindications for hormone therapy; 5) history of regular bleeding patterns on our 
Materials and Methods

Study Design
This open-label pharmacokinetic study consisted of a screening evaluation (previously described, ref. 6), a 2-month control (baseline) period, and a 2-month treatment period.
Screening evaluation (6) was conducted during the prior 3 months, before study enrollment. Each patient returned for interim study visits at weeks 2 and 4 of cycle 2 (E 2 /MPA, baseline period) and weeks 2 and 4 of cycle 4 (E 2 /MPA/TTP, treatment period).
Study protocol
Compliance was determined by a count of the used patches at each visit. 
Scheduled vaginal bleeding patterns, safety, and local skin tolerability assessment
Scheduled vaginal bleeding patterns. A daily bleeding diary was provided to the patients, which required them to record daily the presence of any bleeding and to grade it with respect to amount.
Laboratory and androgenic assessments. Liver function tests and lipids were analyzed during the baseline period and the treatment period. Hirsutism scores were assessed using the Ferriman and Gallwey score (10) .
Skin tolerability assessment. Skin appearance at the current TTP application sites and the surrounding sites were evaluated for any signs of irritation or contact allergy at each clinic visit. Patch adherence was also evaluated at each clinic visit.
Laboratory methods
Liver function tests and lipids were analyzed at the National Institutes of Health Clinical
Center using standard methods. All hormone analyses were performed on frozen serum 7 by Esoterix Endocrinology (Calabasas Hills, CA). Total T and E 2 were measured by specific RIAs after extraction in hexane-ethyl acetate and column chromatography. The free T concentration was determined as the product of the percent free T, measured by equilibrium dialysis, and the total T concentration. SHBG was measured by immunoradiometric assay. Normal ranges for free T, total T and E 2 correspond to an Esoterix database of normal cycling women between the ages of 16 and 46 yr (7). The normal range for SHBG is that reported by Esoterix for premenopausal women.
Statistical Analysis
The primary endpoints of the study were the changes in free and total T levels produced by the TTP. The secondary end points included the possible effects of TTP treatment on estradiol and SHBG levels, and on safety parameters, e.g. vaginal bleeding patterns, hirsutism and acne score, lipid levels, insulin, and liver function tests.
The statistical significance of the differences between free and total T levels at baseline and during TTP treatment was assessed using a paired t-test (2-tail; alpha = 0.05). The statistical analyses were performed using Microsoft Office Excel.
Results
Patient Characteristics and Disposition
The mean age of the patients was 34 years (range, 28-41 years of age). Six women were white, one was black and one was Hispanic. The mean (SEM) BMI was 24.7 (0.6) kg/m 2 .
All eight patients completed the four treatment cycles and pharmacokinetic evaluations. (Fig. 1 ). There were no statistically significant effects of MPA treatment (week 2 vs. week 4) on any of the pharmacokinetic parameters for free and total T ( Table 1 ).
The time-average estradiol levels (Cavg) averaged approximately 117 pg/mL (429.5
pmol/L) and showed no significant influence of the concomitant TTP or MPA administrations, indicating negligible systemic conversion of testosterone to estradiol, or an influence of MPA on estradiol clearance ( Table 1 ). The SHBG levels showed little variation over the 96-hour sampling periods and fell within the normal range for premenopausal women (40 to 120 nmol/L). There was a small (~10%) but statistically significant decrease in SHBG levels during TTP treatment at week 2 (P=0.048) and week 4 (P=0.031) and a similar decrease with MPA observed during cycle 4 (P=0.019) ( Table   1 ).
Safety Parameters
Scheduled vaginal bleeding patterns. While on transdermal testosterone administration, the patients continued to have scheduled vaginal bleeding patterns, with no significant Local skin tolerability assessment. No patient had to discontinue usage related to local skin irritation.
Discussion
We report the first study using an investigational testosterone transdermal patch in young women with sPOF. In this short-term study, the TTP was well tolerated and had no adverse effect on scheduled vaginal bleeding patterns.
Most studies have shown that women with sPOF have significantly lower testosterone levels than regularly menstruating women (3) (4) (5) . Hypoandrogenism might explain why two-thirds of young women with sPOF have significantly reduced bone mineral density, despite taking standard estrogen/progestogen hormone therapy (11) . Increasing evidence suggests that androgens have important biological roles in women, such as maintaining bone mass (12) (13) (14) , and normal sexual function (9, 12) . This raises the possibility that androgen in addition to estrogen therapy may be necessary for adequate sex-steroid replacement therapy in women with sPOF. 10 The TTP used in this protocol has been previously tested in surgically menopausal women with impaired sexual function (9) and androgen deficient women with HIV/AIDS (7, 8 ), but has not been used in young women with sPOF and an intact uterus.
Combining the results obtained with and without concomitant MPA, the mean timeaveraged increments in serum free and total T levels were 4.8 pg/mL (16.6 pmol/L) and 34 ng/dL (1.17 nmol/L), respectively. These increments are somewhat greater than observed in a prior pharmacokinetic study of the 150 mcg/day patches in 11
oophorectomized women who were withdrawn from estrogen therapy (15) . Differences in the clearance rate of testosterone and body mass index in the two groups (i.e., less body fat in young women with sPOF) may account for the different findings.
Women with sPOF are younger, compared with oophorectomized women, and have normal adrenal androgen production (2). Therefore, young women with sPOF may require smaller doses of TTP, designed to achieve ovarian testosterone production (i.e.,
mcg/d).
An important factor influencing testosterone clearance is the level of SHBG, which binds testosterone and lowers its free fraction. Oral estrogens produce a marked dose-dependent increase in SHBG levels; whereas oral androgens produce a marked decrease (16) .
Androgenic progestogens given orally also lower SHBG levels (16) . In contrast, transdermal estradiol and testosterone exert weaker hepatic effects and have a smaller influence on SHBG levels (17) . In our study the women with sPOF received transdermal estradiol patches and had SHBG levels within the normal range. As expected (16), during To convert free T levels from pg/mL to pmol/L, multiply by 3.467. To convert total T levels from ng/dL to nmol/L, multiply by 0.034. C. D.
